Mergers & acquisitions
In a deal set to be finalized early in 2021, Urovant Sciences has agreed to be fully acquired by largest investor and close partner, Sumitovant Biopharma.
This morning, the company announced it bolstered its own gene therapy activities with the acquisition of Handl Therapeutics BV, a rapidly growing and transformative gene therapy company.
Setbacks and delays caused by COVID-19 are making everyone, in every facet of life, nervous. This week, that includes legacy Celgene CVR investors who are staging a mass exodus as two drugs under the agreement near the deadline and one, Liso-cel, faces inspection delays.
Shares of Endo International are up more than 5% after the company announced positive earnings Thursday and also announced a new restructuring plan.
Denmark’s Novo Nordisk is acquiring New Jersey-based Emisphere Technologies in a deal worth about $1.8 billion. Novo Nordisk and Emisphere have been partnered since 2007.
The current pandemic has caused a major decrease in big money investments into mergers and acquisitions. Could company collaborations be the skeleton key needed to drive life sciences?
Merck is dropping $2.75 billion to acquire a promising cancer therapy that targets receptor tyrosine kinase-like orphan receptor 1 (ROR1) in both hematological and solid tumors.
On October 30, the company announced the acquisition of long-time collaborator Oscine Corp.
Pfizer and Mylan are less than two weeks away from finalizing the merger of the generic drugmaker with Pfizer’s Upjohn business unit.
Horizon Discovery Group brings new gene editing and gene modulation tools to PerkinElmer’s expanding life sciences portfolio.
PRESS RELEASES